Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Palisade Bio regains compliance with Nasdaq listing requirements » 14:45
12/01/22
12/01
14:45
12/01/22
14:45
PALI

Palisade Bio

$3.89 /

+0.09 (+2.37%)

Palisade Bio announced…

Palisade Bio announced that on December 1, 2022, it received notice from The Nasdaq Stock Market LLC that it has regained compliance with the Nasdaq Listing Rules for continued listing on The Nasdaq Capital Market.

ShowHide Related Items >><<
PALI Palisade Bio
$3.89 /

+0.09 (+2.37%)

PALI Palisade Bio
$3.89 /

+0.09 (+2.37%)

08/19/22 Maxim
Palisade Bio downgraded to Hold from Buy at Maxim
02/02/22 Ladenburg
Palisade Bio initiated with a Buy at Ladenburg
PALI Palisade Bio
$3.89 /

+0.09 (+2.37%)

Over a week ago
Hot Stocks
Palisade Bio granted Fast Track designation from FDA for LB1148 » 08:36
11/22/22
11/22
08:36
11/22/22
08:36
PALI

Palisade Bio

$2.20 /

-0.27 (-10.93%)

Palisade Bio announced…

Palisade Bio announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to LB1148 for the acceleration of time to return of bowel function following surgery. LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, with the potential to both reduce abdominal adhesions and accelerate the return of bowel function following gastrointestinal surgery. "Receiving Fast Track designation represents an important regulatory milestone for the Company. Although our current focus is on our adhesions study, this designation provides what we believe is a key component to our future clinical and regulatory strategies as we continue to formulate next steps for studying the return of bowel function," commented JD Finley, interim CEO of Palisade Bio.

ShowHide Related Items >><<
PALI Palisade Bio
$2.20 /

-0.27 (-10.93%)

PALI Palisade Bio
$2.20 /

-0.27 (-10.93%)

08/19/22 Maxim
Palisade Bio downgraded to Hold from Buy at Maxim
02/02/22 Ladenburg
Palisade Bio initiated with a Buy at Ladenburg
PALI Palisade Bio
$2.20 /

-0.27 (-10.93%)

Hot Stocks
Palisade Bio appoints Slade as Chief Medical Officer » 08:09
11/18/22
11/18
08:09
11/18/22
08:09
PALI

Palisade Bio

$2.58 /

-0.17 (-6.18%)

Palisade Bio announced…

Palisade Bio announced the appointment of Herbert Slade, MD, FAAAAI as Chief Medical Officer of Palisade Bio. Dr. Slade is a proven medical and regulatory professional with over 25 years of leadership experience in the pharmaceutical and medical device industries. Dr. Slade currently serves as the Adjunct Clinical Associate Professor, Dept. of Pediatrics, Texas College of Osteopathic Medicine, UNTHSC and as Treasurer and member of the Board of Directors of The Wound Healing Society. He joins Palisade Bio having most recently served as the President and Managing Director of Chisholm Clinical Research Services.

ShowHide Related Items >><<
PALI Palisade Bio
$2.58 /

-0.17 (-6.18%)

PALI Palisade Bio
$2.58 /

-0.17 (-6.18%)

08/19/22 Maxim
Palisade Bio downgraded to Hold from Buy at Maxim
02/02/22 Ladenburg
Palisade Bio initiated with a Buy at Ladenburg
PALI Palisade Bio
$2.58 /

-0.17 (-6.18%)

Hot Stocks
Palisade Bio releases explanation of scientific approach of LB1148 » 08:39
11/17/22
11/17
08:39
11/17/22
08:39
PALI

Palisade Bio

$2.75 /

-0.51 (-15.64%)

Palisade Bio announces…

Palisade Bio announces the release of its new animated video for its lead asset in development, LB1148. The video can be accessed here. The Company's lead product candidate, LB1148, is a novel oral liquid formulation of the well-characterized digestive enzyme inhibitor tranexamic acid, with the potential to both reduce abdominal adhesions and accelerate the return of bowel function following surgery. LB1148 is currently being developed for administration prior to GI surgeries requiring bowel resection, disrupting the intestinal epithelial barrier. By inhibiting the activity of digestive proteases, the Company believes that LB1148 has the potential to reduce the formation of adhesions in GI tissues and accelerate the time to the return of normal GI function. "LB1148 has continued to demonstrate its therapeutic potential across a broad range of conditions associated with GI barrier dysfunction. This animated video helps to showcase our innovative approach and explain in detail the mechanism of how we believe LB1148 works in protecting intestinal barrier heath," commented JD Finley, Interim CEO.

ShowHide Related Items >><<
PALI Palisade Bio
$2.75 /

-0.51 (-15.64%)

PALI Palisade Bio
$2.75 /

-0.51 (-15.64%)

08/19/22 Maxim
Palisade Bio downgraded to Hold from Buy at Maxim
02/02/22 Ladenburg
Palisade Bio initiated with a Buy at Ladenburg
PALI Palisade Bio
$2.75 /

-0.51 (-15.64%)

Earnings
Palisade Bio reports Q3 EPS (8c) vs 42c last year » 08:51
11/14/22
11/14
08:51
11/14/22
08:51
PALI

Palisade Bio

/

+

J.D. Finley, interim CEO…

J.D. Finley, interim CEO of Palisade, commented, "Our number one priority is advancing the U.S. Phase 2 study of LB1148 for the prevention of post-surgical abdominal adhesions in GI surgery. We are well funded through an interim data readout for this study in the first half of 2023 and topline results in the second half of 2023. Our new leadership along with our Board strongly believe the execution of this strategy will be the catalyst for unlocking significant value for our shareholders in the near-term."

ShowHide Related Items >><<
PALI Palisade Bio
/

+

PALI Palisade Bio
/

+

08/19/22 Maxim
Palisade Bio downgraded to Hold from Buy at Maxim
02/02/22 Ladenburg
Palisade Bio initiated with a Buy at Ladenburg
PALI Palisade Bio
/

+

Over a month ago
Hot Stocks
Palisade Bio CEO Thomas Hallam steps down, JD Finley named interim CEO » 09:27
10/11/22
10/11
09:27
10/11/22
09:27
PALI

Palisade Bio

/

+

Palisade Bio announced an…

Palisade Bio announced an executive leadership transition. Effective October 10, 2022, Thomas Hallam, Ph.D., ceased his duties as CEO. The company's board of directors has appointed JD Finley, current CFO, as interim CEO, and Mr. Finley has assumed the duties of Dr. Hallam effective October 10, 2022. In order to ensure a smooth and timely transition, the company will focus its near-term resources on the internal reorganization. Accordingly, the company will no longer be presenting at the American College of Surgeons Clinical Congress 2022, being held October 16 - 20, 2022.

ShowHide Related Items >><<
PALI Palisade Bio
/

+

PALI Palisade Bio
/

+

08/19/22 Maxim
Palisade Bio downgraded to Hold from Buy at Maxim
02/02/22 Ladenburg
Palisade Bio initiated with a Buy at Ladenburg
PALI Palisade Bio
/

+

Hot Stocks
Palisade Bio announces oral presentation of Phase 2 data at ACS congress » 08:41
09/29/22
09/29
08:41
09/29/22
08:41
PALI

Palisade Bio

/

+

Palisade Bio announced…

Palisade Bio announced its abstract was accepted for presentation at the American College of Surgeons, ACS, Clinical Congress 2022 being held October 16-20, 2022, in San Diego, CA. Details of the abstract presentation are as follows: Title: LB1148 An Enteral Protease Inhibitor Significantly Accelerated the Return of Bowel Function after Bowel Resection. The abstract is now available and can be accessed in the Congress Program Planner. The oral presentation will include new GI functional data sub-cuts from the highly statistically significant Phase 2 clinical study demonstrating LB1148 significantly accelerated the return of post-operative GI function in patients undergoing elective bowel resection. The data sub-cuts are based on laparoscopy and laparotomy with surgical characteristics including, right hemicolectomy, left hemicolectomy, sigmoid and low anterior resection surgery. .

ShowHide Related Items >><<
PALI Palisade Bio
/

+

PALI Palisade Bio
/

+

08/19/22 Maxim
Palisade Bio downgraded to Hold from Buy at Maxim
02/02/22 Ladenburg
Palisade Bio initiated with a Buy at Ladenburg
PALI Palisade Bio
/

+

Hot Stocks
Palisade Bio announces 20% reduction to workforce, focus on LB1148 » 08:35
09/15/22
09/15
08:35
09/15/22
08:35
PALI

Palisade Bio

/

+

Palisade Bio announced…

Palisade Bio announced that following an internal strategic review, the Management Team and Board have implemented initiatives to streamline the organization, reduce operating expenses and preserve capital, with the goal of maximizing the advancement of its lead clinical program, LB1148. "In light of current financial market conditions and our need to advance our lead clinical program, LB1148, it was imperative that we conduct a strategic review to ensure we have sufficient capital to extend our runway as long as possible. In partnership with our Board of Directors we took a serious look internally, evaluating all aspects of our business. As a result of this process, we identified efficiencies and took cost-saving measures of over $1.5 million per annum to streamline our business, including a 20% reduction in our workforce," commented Tom Hallam, Ph.D., CEO of Palisade Bio. "Through these necessary actions, I believe our company is now in a much stronger position financially. As we push forward, we remain steadfast in our commitment to advance LB1148 through our pivotal Phase 3 study for accelerating the return of postoperative bowel function and our Phase 2 study for the prevention of post-surgical abdominal adhesions through the finish line, where we believe we will be able to unlock significant shareholder value."

ShowHide Related Items >><<
PALI Palisade Bio
/

+

PALI Palisade Bio
/

+

08/19/22 Maxim
Palisade Bio downgraded to Hold from Buy at Maxim
02/02/22 Ladenburg
Palisade Bio initiated with a Buy at Ladenburg
PALI Palisade Bio
/

+

Hot Stocks
Palisade Bio to present at Virtual Investor Innovations in Intestinal Health » 09:10
09/13/22
09/13
09:10
09/13/22
09:10
PALI

Palisade Bio

/

+

Palisade Bio announced…

Palisade Bio announced that Tom Hallam, Ph.D., Chief Executive Officer and Michael Dawson, M.D., Chief Medical Officer of Palisade Bio will present at the Virtual Investor Innovations in Intestinal Health - Launching a Pivotal Phase 3 Study for Return of Postoperative Bowel Function Event on Friday, September 16, 2022 at 11:00 AM ET. As part of the virtual event, the company will discuss its recently launched pivotal Phase 3 study designed to assess the safety and efficacy of LB1148 for postoperative return of bowel function. The Phase 3 study is designed as a multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial set to enroll approximately 600 patients. The primary endpoint is time to recovery of the upper and lower gastrointestinal tract following surgery, defined as the time from the end of surgery to the toleration of food and first bowel movement. All patients enrolled in the study will undergo a scheduled bowel resection surgery that will include either laparotomy or minimally invasive surgical approaches. The clinical study will utilize the same dosing of LB1148 used in the company's completed Phase 2 study in which LB1148 demonstrated a 1.1-day improvement in return of bowel function.

ShowHide Related Items >><<
PALI Palisade Bio
/

+

PALI Palisade Bio
/

+

08/19/22 Maxim
Palisade Bio downgraded to Hold from Buy at Maxim
02/02/22 Ladenburg
Palisade Bio initiated with a Buy at Ladenburg
PALI Palisade Bio
/

+

Over a quarter ago
Downgrade
Palisade Bio downgraded to Hold from Buy at Maxim » 08:03
08/19/22
08/19
08:03
08/19/22
08:03
PALI

Palisade Bio

/

+

Maxim analyst Naz Rahman…

Maxim analyst Naz Rahman downgraded Palisade Bio to Hold from Buy after its Q2 results and closed financing. The company's cash balance should provide enough funding into the first half of 2023 but is not sufficient to fully finance operations during the ongoing Phase 3 enrollment period for LB1148 , and includes additional dilution, the analyst tells investors in a research note. Considering the terms of the recent financings, current stock price, and future need for capital at potentially unfavorable terms, there is a likelihood of additional dilution, Rahman adds.

ShowHide Related Items >><<
PALI Palisade Bio
/

+

PALI Palisade Bio
/

+

02/02/22 Ladenburg
Palisade Bio initiated with a Buy at Ladenburg
08/31/21 Maxim
Palisade Bio initiated with a Buy at Maxim
08/31/21 Maxim
Palisade Bio initiated with a Buy at Maxim
PALI Palisade Bio
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.